Pure Global
NCT06379191

The Efficacy of WeChat-based Multidisciplinary Full-course Nutritional Management Program

The Efficacy of WeChat-based Multidisciplinary Full-course Nutritional Management Program on the Nutritional Status of Ovarian Cancer Patients Undergoing Chemotherapy: a Randomized Controlled Trial
Peking Union Medical College Hospital·ClinicalTrials.gov·behavioralCompleted
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Ovarian Cancer
Drug/Device/Intervention
Nutrition intervention model based on WeChat applets
Study type
Interventional
Intervention type
behavioral
Sponsor & location
Primary sponsor
Peking Union Medical College Hospital
Location
Beijing, China
Timeline & enrollment
Phase
N/A
Start date
Feb 01, 2023
End date
Oct 30, 2023
Enrollment
78 participants
Primary outcome

patient-generated subjective global assessment (PG-SGA)

Summary

As the most malignant type of cancer in the female reproductive system, ovarian cancer (OC)
 has become the second leading cause of death among Chinese women. Chemotherapy is the main
 treatment for OC patients, and its numerous adverse effects can easily lead to malnutrition.
 It is difficult to centrally manage OC patients in the intervals between chemotherapy. The
 utility of WeChat, an effective and more cost-efficient mobile tool, in chronic disease
 management has been highlighted.

ICD-10 classifications
Malignant neoplasm of ovarySecondary malignant neoplasm of ovaryBenign neoplasm of ovaryOvarian pregnancyOvarian dysfunction
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06379191
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06379191 through Pure Global AI's free database. This phase not specified trial is sponsored by Peking Union Medical College Hospital and is currently Completed. The study focuses on Ovarian Cancer. Target enrollment is 78 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.